Cancer Clinical Trials
Cancer clinical trials may open new doors of cancer screening, diagnosis and treatment options for you and your loved ones. Oftentimes, these innovative studies can offer better options for specific circumstances than the current standard of care.
Today’s patients discover new hope for better outcomes and quality of life through clinical trials. Future patients benefit from the lessons learned that lead to improved treatment options and cure rates.
What is a Clinical Trial?
A clinical trial – also known as a clinical research study – is designed to answer specific questions about drugs, vaccines, and medical devices, as well as find new ways of using current treatments for other medical conditions. Clinical drug trials help determine if new treatments are both safe and effective, and are the safest way to find treatments that work.
Before testing can begin in humans through a clinical trial, extensive research must be conducted in animal and human cells. If all testing proves successful and promising, sponsors of the clinical trial must receive Food and Drug Administration (FDA) approval before starting to test through a clinical trial.
Interested in learning more about clinical trials? View our participant information or call the Avera Cancer Institute Navigation Center at 888-422-1410.
Clinical Trials for Innovative Cancer Treatment
Through Avera Cancer Institute’s affiliation with the National Cancer Institute and NRG Oncology, Avera patients benefit from access to a variety of innovative treatment options through clinical trials. View our complete list of oncology studies currently enrolling patients and learn more about our Breast Cancer Collaborative Registry.
Avera Cancer Institute Sioux Falls
Brain Cancer Studies
Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.
- We currently have no open studies for this disease site.
Breast Cancer Studies
Cancer Registry Studies
Contact Research Coordinators at (605)322-3086 or (605)322-3295 or (605)322-3018 or (605)322-3295 for more information.
Cancer Screening
Contact Research Coordinators at (605)322-3221 or (605)322-3291 for more information.
- We currently have no open studies.
Colorectal Cancer Studies
Genetics Studies
Contact Research Coordinators at (605)322-3228 or (605)322-3291 for more information.
Gynecologic Cancer Studies
Contact Research Coordinators at (605)322-7536 or email gynresearch@avera.org for more information.
- GOG 0263: Stage I/IIA Cervical Cancer
- GOG 0264: Sex Cord-Stromal Tumors of the Ovary
- GSB: Gynecologic Specimen Bank for Genetic and Genomic Investigation
- Takeda X31025: A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
- Tesaro TNE001: A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancer
- CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy) [Immunotherapy]
- NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer(Immunotherapy) - Temporarily closed 09-May-2019
- 3000-03-005/ENGot-OV44: The FIRST: A randomized, Double-Blind, Phase 3 comparison of platinum-based therapy with TSR 042 and niraparib versus standard of care platinum-based therapy as First line treatment of stage III or IV nonmucinous Epithelial ovarian cancer (Immunotherapy)
- NRG-GY016: A Phase II Study of MK-3475 (Pembrolizumab) + Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary (Immunotherapy)
- NRG-GY014: A Phase II Study of Tazemetostat (EPZ-6438)(IND# 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
- NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
- NRG-GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Head and Neck Cancer Studies
Hepatocellular/Liver Cancer Studies
Immunotherapy Studies
Contact Research Coordinators at (605)322-3086 or (605)322-3291 for more information.
- EA5142 Anvil: Nivolumab after surgery and chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer
- CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
- NSABP B-59/GBG 96-Gepardouze: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
- WIN001: Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination
- NRG-GY016: A Phase II Study of MK-3475 Pembrolizumab+Epacadostat in Recurrent Clear Cell Carcinoma of the Ovary
- A021502: Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
- 3000-03-005/ENGot-OV44: The FIRST: A randomized, Double-Blind, Phase 3 comparison of platinum-based therapy with TSR 042 and niraparib versus standard of care platinum-based therapy as First line treatment of stage III or IV nonmucinous Epithelial ovarian cancer
- A031501: Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
- NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian
- S1418/BR006: A Randomized Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
- NRG-BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
- EA6134: Advanced BRAFV600 Mutant Melanoma
Leukemia Studies
Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.
- We currently have no open studies for this disease site.
Lung Cancer Studies
Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.
- Alchemist: Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery - enrollment temporarily suspended 26-Aug-2019
- S1400: Phase II/III Biomarker-Driven Master Protocol
for Second Line Therapy of Squamous Cell Lung Cancer
- WIN001: Survival Prolongation by Rationale INnovative Genomics (SPRING): A proof of concept study to explore safety and efficacy of tri-therapy approach in advanced/metastatic NSCLC and retrospectively assess the ability of integrated genomics and transcriptomics to match patients to the combination (Immunotherapy)
- D9108C00001: A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Durvalumab Alone or in Combination with Novel Agents in Subjects with Locally Advanced, Unresectable, Stage III Non-small Cell Lung Cancer (COAST)
- D9106C00001: A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)
- D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
Lymphoma Studies
Melanoma Studies
Multiple Myeloma Studies
Myelodysplastic Syndrome Studies
Contact Research Coordinators at (605)322-3090 or email hematologyresearch@avera.org for more information.
- We currently have no open studies for this disease site.
Myelofibrosis Studies
Pancreatic Cancer Studies
Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.
- We currently have no open studies for this disease site.
Prostate Cancer Studies
Contact Research Coordinators at (605)322-3228 or email medoncresearch@avera.org for more information.
- We currently have no open studies for this disease site.
Renal/Urinary Tract Cancer Studies
Transplant/Transfusion Studies
Contact Research Coordinator at (605)322-3016 for more information.
Avera Cancer Institute Aberdeen
Brain Cancer Studies
Breast Cancer Studies
Colorectal Cancer Studies
Genetics Studies
Lung Cancer Studies
Multiple Myeloma Studies
Renal/Urinary Tract Cancer Studies
Cancer Control Studies
Cancer Registry Studies
Avera Cancer Institute Marshall
Avera Cancer Institute Mitchell
